[Effects of different types of treatment on serum HDL-C apoA I and apoB100 in non-insulin dependent diabetes mellitus].
D016632:Apolipoprotein A-I; D053299:Apolipoprotein B-100; D001054:Apolipoproteins A / Q000097:blood*; D001055:Apolipoproteins B / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000628:therapy; D003927:Diet, Diabetic; D005260:Female; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D008297:Male; D013453:Sulfonylurea Compounds / Q000627:therapeutic use
D016632:Apolipoprotein A-I; D053299:Apolipoprotein B-100; D001054:Apolipoproteins A; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D006146:Guanidines; D013453:Sulfonylurea Compounds